No data to show
XNAS
COEPW
Market cap406mUSD
Jul 24, Last price
0.03USD
1D
-22.42%
1Q
73.00%
IPO
-61.56%
Name
Coeptis Therapeutics Holdings Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
300.71%
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L-53.85%
CFO
-7m
L-8.15%
Profile
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 3,277 | 11,628 | 34,196 | ||
Unusual Expense (Income) | |||||
NOPBT | (3,277) | (11,628) | (34,196) | ||
NOPBT Margin | |||||
Operating Taxes | (1,064) | 3,394 | |||
Tax Rate | |||||
NOPAT | (2,213) | (11,628) | (37,590) | ||
Net income | (9,814) -53.85% | (21,267) -48.09% | (40,968) 184.06% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 4,792 | 3,271 | |||
BB yield | -23.80% | -14.94% | |||
| Debt | |||||
Debt current | 1,188 | 1,013 | 1,542 | ||
Long-term debt | 310 | 221 | |||
Deferred revenue | |||||
Other long-term liabilities | 557 | 1,125 | |||
Net debt | (5,036) | (146) | (2,029) | ||
| Cash flow | |||||
Cash from operating activities | (6,649) | (7,240) | (3,876) | ||
CAPEX | 4 | ||||
Cash from investing activities | |||||
Cash from financing activities | 5,713 | 4,917 | 5,488 | ||
FCF | (116) | (11,439) | (37,629) | ||
| Balance | |||||
Cash | 533 | 1,469 | 3,791 | ||
Long term investments | 5,691 | ||||
Excess cash | 6,224 | 1,469 | 3,791 | ||
Stockholders' equity | (97,010) | (87,353) | (65,738) | ||
Invested Capital | 102,593 | 93,448 | 73,372 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 1,925 | 25,690 | 14,296 | ||
Price | 5.50 601.62% | 0.78 -48.81% | 1.53 -62.19% | ||
Market cap | 10,586 -47.44% | 20,138 -8.01% | 21,891 -73.56% | ||
EV | 6,231 | 19,993 | 19,862 | ||
EBITDA | (2,239) | (10,626) | (33,195) | ||
EV/EBITDA | |||||
Interest | 396 | 108 | 218 | ||
Interest/NOPBT | |||||